nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—PDGFRA—brain cancer	0.306	0.663	CbGaD
Sorafenib—CYP2C9—brain cancer	0.155	0.336	CbGaD
Sorafenib—UGT1A1—Etoposide—brain cancer	0.0283	0.127	CbGbCtD
Sorafenib—CYP2D6—Lomustine—brain cancer	0.0219	0.0982	CbGbCtD
Sorafenib—CYP1A2—Carmustine—brain cancer	0.0217	0.0972	CbGbCtD
Sorafenib—ABCC2—Carboplatin—brain cancer	0.0205	0.092	CbGbCtD
Sorafenib—ABCG2—Carboplatin—brain cancer	0.0186	0.0832	CbGbCtD
Sorafenib—ABCC2—Etoposide—brain cancer	0.0172	0.0773	CbGbCtD
Sorafenib—CYP2D6—Hydroxyurea—brain cancer	0.0166	0.0744	CbGbCtD
Sorafenib—CYP3A4—Temozolomide—brain cancer	0.0164	0.0734	CbGbCtD
Sorafenib—ABCG2—Etoposide—brain cancer	0.0156	0.0698	CbGbCtD
Sorafenib—CYP3A4—Lomustine—brain cancer	0.0139	0.0624	CbGbCtD
Sorafenib—CYP3A5—Etoposide—brain cancer	0.00863	0.0387	CbGbCtD
Sorafenib—CYP2C8—Etoposide—brain cancer	0.0083	0.0372	CbGbCtD
Sorafenib—CYP1A2—Etoposide—brain cancer	0.00643	0.0288	CbGbCtD
Sorafenib—ABCB1—Etoposide—brain cancer	0.00562	0.0252	CbGbCtD
Sorafenib—CYP3A4—Etoposide—brain cancer	0.00337	0.0151	CbGbCtD
Sorafenib—Vismodegib—SHH—brain cancer	0.00286	0.422	CrCbGaD
Sorafenib—Vismodegib—SMO—brain cancer	0.00164	0.242	CrCbGaD
Sorafenib—Regorafenib—PDGFRA—brain cancer	0.00119	0.176	CrCbGaD
Sorafenib—Regorafenib—CYP2C9—brain cancer	0.000603	0.0891	CrCbGaD
Sorafenib—Vismodegib—CYP2C9—brain cancer	0.000478	0.0706	CrCbGaD
Sorafenib—RAF1—brainstem—brain cancer	0.000374	0.00411	CbGeAlD
Sorafenib—CDK7—central nervous system—brain cancer	0.000374	0.0041	CbGeAlD
Sorafenib—EPHA6—head—brain cancer	0.000373	0.0041	CbGeAlD
Sorafenib—MAPK11—cerebellum—brain cancer	0.000371	0.00408	CbGeAlD
Sorafenib—AURKC—central nervous system—brain cancer	0.000368	0.00404	CbGeAlD
Sorafenib—CDK7—cerebellum—brain cancer	0.000365	0.00401	CbGeAlD
Sorafenib—TAOK2—cerebellum—brain cancer	0.000362	0.00398	CbGeAlD
Sorafenib—ZAK—endocrine gland—brain cancer	0.000358	0.00394	CbGeAlD
Sorafenib—BRAF—midbrain—brain cancer	0.000358	0.00393	CbGeAlD
Sorafenib—ZAK—head—brain cancer	0.000354	0.00389	CbGeAlD
Sorafenib—RALBP1—telencephalon—brain cancer	0.000351	0.00386	CbGeAlD
Sorafenib—HIPK3—endocrine gland—brain cancer	0.000351	0.00385	CbGeAlD
Sorafenib—FGFR1—pituitary gland—brain cancer	0.000345	0.00379	CbGeAlD
Sorafenib—HIPK4—brain—brain cancer	0.000342	0.00376	CbGeAlD
Sorafenib—EPHA6—central nervous system—brain cancer	0.000341	0.00374	CbGeAlD
Sorafenib—MAP3K19—head—brain cancer	0.000339	0.00373	CbGeAlD
Sorafenib—FLT1—telencephalon—brain cancer	0.000334	0.00367	CbGeAlD
Sorafenib—FGFR1—medulla oblongata—brain cancer	0.000333	0.00366	CbGeAlD
Sorafenib—RAF1—telencephalon—brain cancer	0.000332	0.00365	CbGeAlD
Sorafenib—EPHB6—telencephalon—brain cancer	0.00033	0.00362	CbGeAlD
Sorafenib—MAP3K7—pituitary gland—brain cancer	0.000327	0.00359	CbGeAlD
Sorafenib—MKNK2—gonad—brain cancer	0.000324	0.00356	CbGeAlD
Sorafenib—TIE1—head—brain cancer	0.000324	0.00355	CbGeAlD
Sorafenib—ZAK—central nervous system—brain cancer	0.000323	0.00355	CbGeAlD
Sorafenib—Skin exfoliation—Etoposide—brain cancer	0.000322	0.00344	CcSEcCtD
Sorafenib—MKNK1—gonad—brain cancer	0.00032	0.00352	CbGeAlD
Sorafenib—MAP2K5—brainstem—brain cancer	0.000318	0.00349	CbGeAlD
Sorafenib—Hyponatraemia—Carmustine—brain cancer	0.000318	0.0034	CcSEcCtD
Sorafenib—Neuropathy—Etoposide—brain cancer	0.000317	0.00338	CcSEcCtD
Sorafenib—MKNK2—pituitary gland—brain cancer	0.000317	0.00348	CbGeAlD
Sorafenib—Neutropenia—Hydroxyurea—brain cancer	0.000316	0.00338	CcSEcCtD
Sorafenib—ZAK—cerebellum—brain cancer	0.000316	0.00347	CbGeAlD
Sorafenib—MAP3K7—medulla oblongata—brain cancer	0.000315	0.00346	CbGeAlD
Sorafenib—PDGFRA—telencephalon—brain cancer	0.000313	0.00344	CbGeAlD
Sorafenib—Arrhythmia—Procarbazine—brain cancer	0.000313	0.00334	CcSEcCtD
Sorafenib—MKNK1—pituitary gland—brain cancer	0.000313	0.00343	CbGeAlD
Sorafenib—MAP3K19—central nervous system—brain cancer	0.00031	0.0034	CbGeAlD
Sorafenib—Body temperature increased—Lomustine—brain cancer	0.00031	0.00331	CcSEcCtD
Sorafenib—Alopecia—Procarbazine—brain cancer	0.000309	0.0033	CcSEcCtD
Sorafenib—HIPK3—cerebellum—brain cancer	0.000309	0.00339	CbGeAlD
Sorafenib—RET—pituitary gland—brain cancer	0.000309	0.00339	CbGeAlD
Sorafenib—MKNK2—medulla oblongata—brain cancer	0.000305	0.00335	CbGeAlD
Sorafenib—Mouth ulceration—Etoposide—brain cancer	0.000305	0.00326	CcSEcCtD
Sorafenib—FGFR1—midbrain—brain cancer	0.000304	0.00334	CbGeAlD
Sorafenib—Infestation—Hydroxyurea—brain cancer	0.000302	0.00322	CcSEcCtD
Sorafenib—Infestation NOS—Hydroxyurea—brain cancer	0.000302	0.00322	CcSEcCtD
Sorafenib—MKNK1—medulla oblongata—brain cancer	0.000302	0.00331	CbGeAlD
Sorafenib—MAPK11—brain—brain cancer	0.000302	0.00331	CbGeAlD
Sorafenib—FLT3—endocrine gland—brain cancer	0.000298	0.00327	CbGeAlD
Sorafenib—RET—medulla oblongata—brain cancer	0.000298	0.00327	CbGeAlD
Sorafenib—FGFR1—spinal cord—brain cancer	0.000297	0.00326	CbGeAlD
Sorafenib—CDK7—brain—brain cancer	0.000297	0.00326	CbGeAlD
Sorafenib—Neuropathy peripheral—Hydroxyurea—brain cancer	0.000296	0.00316	CcSEcCtD
Sorafenib—TIE1—central nervous system—brain cancer	0.000295	0.00324	CbGeAlD
Sorafenib—TAOK2—brain—brain cancer	0.000294	0.00323	CbGeAlD
Sorafenib—Stomatitis—Hydroxyurea—brain cancer	0.000294	0.00314	CcSEcCtD
Sorafenib—AURKC—brain—brain cancer	0.000292	0.00321	CbGeAlD
Sorafenib—Mood swings—Temozolomide—brain cancer	0.00029	0.0031	CcSEcCtD
Sorafenib—TIE1—cerebellum—brain cancer	0.000289	0.00317	CbGeAlD
Sorafenib—MAP3K7—midbrain—brain cancer	0.000288	0.00316	CbGeAlD
Sorafenib—Hypokalaemia—Carmustine—brain cancer	0.000288	0.00308	CcSEcCtD
Sorafenib—RALBP1—pituitary gland—brain cancer	0.000286	0.00314	CbGeAlD
Sorafenib—Hepatobiliary disease—Hydroxyurea—brain cancer	0.000285	0.00305	CcSEcCtD
Sorafenib—Dehydration—Temozolomide—brain cancer	0.000284	0.00304	CcSEcCtD
Sorafenib—MAP2K5—telencephalon—brain cancer	0.000282	0.0031	CbGeAlD
Sorafenib—KIT—brainstem—brain cancer	0.000282	0.0031	CbGeAlD
Sorafenib—Anaemia—Procarbazine—brain cancer	0.000282	0.00301	CcSEcCtD
Sorafenib—MAP3K7—spinal cord—brain cancer	0.000281	0.00309	CbGeAlD
Sorafenib—Dry skin—Temozolomide—brain cancer	0.00028	0.003	CcSEcCtD
Sorafenib—MKNK2—midbrain—brain cancer	0.000279	0.00307	CbGeAlD
Sorafenib—FLT1—gonad—brain cancer	0.000279	0.00306	CbGeAlD
Sorafenib—Hypokalaemia—Temozolomide—brain cancer	0.000278	0.00297	CcSEcCtD
Sorafenib—RAF1—gonad—brain cancer	0.000277	0.00304	CbGeAlD
Sorafenib—BRAF—cerebellum—brain cancer	0.000277	0.00304	CbGeAlD
Sorafenib—Breast disorder—Temozolomide—brain cancer	0.000276	0.00295	CcSEcCtD
Sorafenib—RALBP1—medulla oblongata—brain cancer	0.000276	0.00303	CbGeAlD
Sorafenib—MKNK1—midbrain—brain cancer	0.000276	0.00303	CbGeAlD
Sorafenib—CSF1R—telencephalon—brain cancer	0.000275	0.00303	CbGeAlD
Sorafenib—Toxic epidermal necrolysis—Temozolomide—brain cancer	0.000275	0.00294	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Temozolomide—brain cancer	0.000275	0.00294	CcSEcCtD
Sorafenib—UGT1A9—endocrine gland—brain cancer	0.000275	0.00302	CbGeAlD
Sorafenib—Dysphagia—Carmustine—brain cancer	0.000274	0.00292	CcSEcCtD
Sorafenib—Syncope—Procarbazine—brain cancer	0.000273	0.00292	CcSEcCtD
Sorafenib—Leukopenia—Procarbazine—brain cancer	0.000273	0.00291	CcSEcCtD
Sorafenib—MKNK2—spinal cord—brain cancer	0.000272	0.00299	CbGeAlD
Sorafenib—RET—midbrain—brain cancer	0.000272	0.00299	CbGeAlD
Sorafenib—Haemoglobin—Hydroxyurea—brain cancer	0.000272	0.00291	CcSEcCtD
Sorafenib—FLT1—pituitary gland—brain cancer	0.000272	0.00299	CbGeAlD
Sorafenib—FLT4—endocrine gland—brain cancer	0.000271	0.00297	CbGeAlD
Sorafenib—Haemorrhage—Hydroxyurea—brain cancer	0.000271	0.00289	CcSEcCtD
Sorafenib—EPHA6—brain—brain cancer	0.00027	0.00297	CbGeAlD
Sorafenib—RAF1—pituitary gland—brain cancer	0.00027	0.00297	CbGeAlD
Sorafenib—Cardiac failure congestive—Etoposide—brain cancer	0.00027	0.00288	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Temozolomide—brain cancer	0.00027	0.00288	CcSEcCtD
Sorafenib—MKNK1—spinal cord—brain cancer	0.000269	0.00295	CbGeAlD
Sorafenib—EPHB6—pituitary gland—brain cancer	0.000269	0.00295	CbGeAlD
Sorafenib—Loss of consciousness—Procarbazine—brain cancer	0.000268	0.00286	CcSEcCtD
Sorafenib—FLT4—head—brain cancer	0.000267	0.00294	CbGeAlD
Sorafenib—Cough—Procarbazine—brain cancer	0.000266	0.00284	CcSEcCtD
Sorafenib—RET—spinal cord—brain cancer	0.000266	0.00292	CbGeAlD
Sorafenib—EPHX2—cerebellum—brain cancer	0.000265	0.0029	CbGeAlD
Sorafenib—Dysphagia—Temozolomide—brain cancer	0.000264	0.00282	CcSEcCtD
Sorafenib—STK10—gonad—brain cancer	0.000264	0.0029	CbGeAlD
Sorafenib—Hypertension—Procarbazine—brain cancer	0.000263	0.00281	CcSEcCtD
Sorafenib—FLT3—cerebellum—brain cancer	0.000263	0.00288	CbGeAlD
Sorafenib—FLT1—medulla oblongata—brain cancer	0.000262	0.00288	CbGeAlD
Sorafenib—PDGFRA—gonad—brain cancer	0.000261	0.00287	CbGeAlD
Sorafenib—RAF1—medulla oblongata—brain cancer	0.000261	0.00286	CbGeAlD
Sorafenib—Arthralgia—Procarbazine—brain cancer	0.000259	0.00277	CcSEcCtD
Sorafenib—Myalgia—Procarbazine—brain cancer	0.000259	0.00277	CcSEcCtD
Sorafenib—EPHB6—medulla oblongata—brain cancer	0.000259	0.00285	CbGeAlD
Sorafenib—ZAK—brain—brain cancer	0.000256	0.00282	CbGeAlD
Sorafenib—Neutropenia—Carmustine—brain cancer	0.000256	0.00273	CcSEcCtD
Sorafenib—Dry mouth—Procarbazine—brain cancer	0.000254	0.00271	CcSEcCtD
Sorafenib—RALBP1—midbrain—brain cancer	0.000252	0.00277	CbGeAlD
Sorafenib—HIPK3—brain—brain cancer	0.000251	0.00276	CbGeAlD
Sorafenib—Cardiac failure—Etoposide—brain cancer	0.000251	0.00268	CcSEcCtD
Sorafenib—KIT—telencephalon—brain cancer	0.00025	0.00275	CbGeAlD
Sorafenib—Vomiting—Lomustine—brain cancer	0.000249	0.00266	CcSEcCtD
Sorafenib—Neutropenia—Temozolomide—brain cancer	0.000247	0.00264	CcSEcCtD
Sorafenib—Infection—Procarbazine—brain cancer	0.000247	0.00264	CcSEcCtD
Sorafenib—RALBP1—spinal cord—brain cancer	0.000246	0.0027	CbGeAlD
Sorafenib—MAP3K19—brain—brain cancer	0.000246	0.0027	CbGeAlD
Sorafenib—Angiopathy—Hydroxyurea—brain cancer	0.000246	0.00263	CcSEcCtD
Sorafenib—Pneumonia—Carmustine—brain cancer	0.000245	0.00262	CcSEcCtD
Sorafenib—MKNK2—endocrine gland—brain cancer	0.000245	0.00269	CbGeAlD
Sorafenib—Shock—Procarbazine—brain cancer	0.000245	0.00261	CcSEcCtD
Sorafenib—PDGFRB—telencephalon—brain cancer	0.000244	0.00268	CbGeAlD
Sorafenib—Erectile dysfunction—Temozolomide—brain cancer	0.000243	0.0026	CcSEcCtD
Sorafenib—Thrombocytopenia—Procarbazine—brain cancer	0.000243	0.0026	CcSEcCtD
Sorafenib—MKNK1—endocrine gland—brain cancer	0.000242	0.00266	CbGeAlD
Sorafenib—MKNK2—head—brain cancer	0.000242	0.00266	CbGeAlD
Sorafenib—FLT1—midbrain—brain cancer	0.00024	0.00263	CbGeAlD
Sorafenib—Renal failure—Carmustine—brain cancer	0.00024	0.00256	CcSEcCtD
Sorafenib—Alopecia—Hydroxyurea—brain cancer	0.000239	0.00256	CcSEcCtD
Sorafenib—Weight decreased—Temozolomide—brain cancer	0.000239	0.00256	CcSEcCtD
Sorafenib—RET—endocrine gland—brain cancer	0.000239	0.00263	CbGeAlD
Sorafenib—Neuropathy peripheral—Carmustine—brain cancer	0.000239	0.00255	CcSEcCtD
Sorafenib—MKNK1—head—brain cancer	0.000239	0.00262	CbGeAlD
Sorafenib—RAF1—midbrain—brain cancer	0.000238	0.00262	CbGeAlD
Sorafenib—Stomatitis—Carmustine—brain cancer	0.000238	0.00254	CcSEcCtD
Sorafenib—Pneumonia—Temozolomide—brain cancer	0.000237	0.00253	CcSEcCtD
Sorafenib—EPHB6—midbrain—brain cancer	0.000237	0.0026	CbGeAlD
Sorafenib—Anorexia—Procarbazine—brain cancer	0.000237	0.00253	CcSEcCtD
Sorafenib—RET—head—brain cancer	0.000236	0.00259	CbGeAlD
Sorafenib—Erythema—Hydroxyurea—brain cancer	0.000236	0.00252	CcSEcCtD
Sorafenib—Infestation—Temozolomide—brain cancer	0.000236	0.00252	CcSEcCtD
Sorafenib—Infestation NOS—Temozolomide—brain cancer	0.000236	0.00252	CcSEcCtD
Sorafenib—FGFR1—cerebellum—brain cancer	0.000235	0.00258	CbGeAlD
Sorafenib—TIE1—brain—brain cancer	0.000235	0.00258	CbGeAlD
Sorafenib—FLT1—spinal cord—brain cancer	0.000234	0.00257	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.000234	0.0025	CcSEcCtD
Sorafenib—Nausea—Lomustine—brain cancer	0.000233	0.00249	CcSEcCtD
Sorafenib—RAF1—spinal cord—brain cancer	0.000233	0.00255	CbGeAlD
Sorafenib—HTR2C—brainstem—brain cancer	0.000232	0.00255	CbGeAlD
Sorafenib—EPHB6—spinal cord—brain cancer	0.000231	0.00254	CbGeAlD
Sorafenib—Neuropathy peripheral—Temozolomide—brain cancer	0.000231	0.00247	CcSEcCtD
Sorafenib—CSF1R—gonad—brain cancer	0.00023	0.00252	CbGeAlD
Sorafenib—KDR—pituitary gland—brain cancer	0.00023	0.00252	CbGeAlD
Sorafenib—MAP2K5—pituitary gland—brain cancer	0.00023	0.00252	CbGeAlD
Sorafenib—Stomatitis—Temozolomide—brain cancer	0.00023	0.00246	CcSEcCtD
Sorafenib—CYP3A7—endocrine gland—brain cancer	0.000228	0.00251	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000227	0.00242	CcSEcCtD
Sorafenib—BRAF—brain—brain cancer	0.000225	0.00247	CbGeAlD
Sorafenib—CSF1R—pituitary gland—brain cancer	0.000224	0.00246	CbGeAlD
Sorafenib—Hepatobiliary disease—Temozolomide—brain cancer	0.000223	0.00238	CcSEcCtD
Sorafenib—MAP3K7—cerebellum—brain cancer	0.000223	0.00245	CbGeAlD
Sorafenib—MAP2K5—medulla oblongata—brain cancer	0.000222	0.00244	CbGeAlD
Sorafenib—KDR—medulla oblongata—brain cancer	0.000222	0.00244	CbGeAlD
Sorafenib—RALBP1—endocrine gland—brain cancer	0.000221	0.00243	CbGeAlD
Sorafenib—MKNK2—central nervous system—brain cancer	0.000221	0.00243	CbGeAlD
Sorafenib—Toxic epidermal necrolysis—Etoposide—brain cancer	0.00022	0.00236	CcSEcCtD
Sorafenib—Haemoglobin—Carmustine—brain cancer	0.00022	0.00235	CcSEcCtD
Sorafenib—PDGFRA—spinal cord—brain cancer	0.000219	0.00241	CbGeAlD
Sorafenib—Haemorrhage—Carmustine—brain cancer	0.000219	0.00234	CcSEcCtD
Sorafenib—RALBP1—head—brain cancer	0.000219	0.0024	CbGeAlD
Sorafenib—MKNK1—central nervous system—brain cancer	0.000218	0.0024	CbGeAlD
Sorafenib—Anaemia—Hydroxyurea—brain cancer	0.000218	0.00233	CcSEcCtD
Sorafenib—CSF1R—medulla oblongata—brain cancer	0.000216	0.00238	CbGeAlD
Sorafenib—Decreased appetite—Procarbazine—brain cancer	0.000216	0.00231	CcSEcCtD
Sorafenib—MKNK2—cerebellum—brain cancer	0.000216	0.00237	CbGeAlD
Sorafenib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000216	0.00231	CcSEcCtD
Sorafenib—RET—central nervous system—brain cancer	0.000215	0.00237	CbGeAlD
Sorafenib—Connective tissue disorder—Carmustine—brain cancer	0.000215	0.0023	CcSEcCtD
Sorafenib—EPHX2—brain—brain cancer	0.000215	0.00236	CbGeAlD
Sorafenib—Fatigue—Procarbazine—brain cancer	0.000214	0.00229	CcSEcCtD
Sorafenib—MKNK1—cerebellum—brain cancer	0.000213	0.00234	CbGeAlD
Sorafenib—Haemoglobin—Temozolomide—brain cancer	0.000213	0.00227	CcSEcCtD
Sorafenib—Constipation—Procarbazine—brain cancer	0.000213	0.00227	CcSEcCtD
Sorafenib—Pain—Procarbazine—brain cancer	0.000213	0.00227	CcSEcCtD
Sorafenib—Haemorrhage—Temozolomide—brain cancer	0.000212	0.00226	CcSEcCtD
Sorafenib—Dysphagia—Etoposide—brain cancer	0.000212	0.00226	CcSEcCtD
Sorafenib—Leukopenia—Hydroxyurea—brain cancer	0.000211	0.00226	CcSEcCtD
Sorafenib—RET—cerebellum—brain cancer	0.000211	0.00231	CbGeAlD
Sorafenib—FLT1—endocrine gland—brain cancer	0.000211	0.00231	CbGeAlD
Sorafenib—RAF1—endocrine gland—brain cancer	0.000209	0.0023	CbGeAlD
Sorafenib—Urinary tract disorder—Temozolomide—brain cancer	0.000209	0.00223	CcSEcCtD
Sorafenib—KIT—gonad—brain cancer	0.000209	0.00229	CbGeAlD
Sorafenib—FLT1—head—brain cancer	0.000208	0.00228	CbGeAlD
Sorafenib—Connective tissue disorder—Temozolomide—brain cancer	0.000208	0.00222	CcSEcCtD
Sorafenib—Urethral disorder—Temozolomide—brain cancer	0.000207	0.00222	CcSEcCtD
Sorafenib—RAF1—head—brain cancer	0.000207	0.00227	CbGeAlD
Sorafenib—HTR2C—telencephalon—brain cancer	0.000206	0.00226	CbGeAlD
Sorafenib—EPHB6—head—brain cancer	0.000206	0.00226	CbGeAlD
Sorafenib—PDGFRB—gonad—brain cancer	0.000204	0.00224	CbGeAlD
Sorafenib—KIT—pituitary gland—brain cancer	0.000204	0.00224	CbGeAlD
Sorafenib—Gastrointestinal pain—Procarbazine—brain cancer	0.000203	0.00217	CcSEcCtD
Sorafenib—Flushing—Carmustine—brain cancer	0.000203	0.00217	CcSEcCtD
Sorafenib—MAP2K5—midbrain—brain cancer	0.000203	0.00223	CbGeAlD
Sorafenib—KDR—midbrain—brain cancer	0.000203	0.00223	CbGeAlD
Sorafenib—Erythema multiforme—Temozolomide—brain cancer	0.0002	0.00214	CcSEcCtD
Sorafenib—RALBP1—central nervous system—brain cancer	0.0002	0.00219	CbGeAlD
Sorafenib—STK10—endocrine gland—brain cancer	0.000199	0.00219	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000199	0.00213	CcSEcCtD
Sorafenib—PDGFRB—pituitary gland—brain cancer	0.000199	0.00218	CbGeAlD
Sorafenib—CSF1R—midbrain—brain cancer	0.000198	0.00217	CbGeAlD
Sorafenib—Neutropenia—Etoposide—brain cancer	0.000198	0.00211	CcSEcCtD
Sorafenib—KDR—spinal cord—brain cancer	0.000198	0.00217	CbGeAlD
Sorafenib—MAP2K5—spinal cord—brain cancer	0.000198	0.00217	CbGeAlD
Sorafenib—Urticaria—Procarbazine—brain cancer	0.000198	0.00211	CcSEcCtD
Sorafenib—PDGFRA—endocrine gland—brain cancer	0.000197	0.00217	CbGeAlD
Sorafenib—Tinnitus—Temozolomide—brain cancer	0.000197	0.00211	CcSEcCtD
Sorafenib—STK10—head—brain cancer	0.000197	0.00216	CbGeAlD
Sorafenib—KIT—medulla oblongata—brain cancer	0.000197	0.00216	CbGeAlD
Sorafenib—Abdominal pain—Procarbazine—brain cancer	0.000197	0.0021	CcSEcCtD
Sorafenib—Body temperature increased—Procarbazine—brain cancer	0.000197	0.0021	CcSEcCtD
Sorafenib—Flushing—Temozolomide—brain cancer	0.000196	0.0021	CcSEcCtD
Sorafenib—Cardiac disorder—Temozolomide—brain cancer	0.000196	0.0021	CcSEcCtD
Sorafenib—Arrhythmia—Carmustine—brain cancer	0.000196	0.00209	CcSEcCtD
Sorafenib—RALBP1—cerebellum—brain cancer	0.000195	0.00214	CbGeAlD
Sorafenib—PDGFRA—head—brain cancer	0.000195	0.00214	CbGeAlD
Sorafenib—FLT4—brain—brain cancer	0.000194	0.00213	CbGeAlD
Sorafenib—HTR2B—telencephalon—brain cancer	0.000193	0.00212	CbGeAlD
Sorafenib—Alopecia—Carmustine—brain cancer	0.000193	0.00207	CcSEcCtD
Sorafenib—CSF1R—spinal cord—brain cancer	0.000193	0.00212	CbGeAlD
Sorafenib—PDGFRB—medulla oblongata—brain cancer	0.000192	0.00211	CbGeAlD
Sorafenib—Angiopathy—Temozolomide—brain cancer	0.000192	0.00205	CcSEcCtD
Sorafenib—Mental disorder—Carmustine—brain cancer	0.000192	0.00205	CcSEcCtD
Sorafenib—FGFR1—brain—brain cancer	0.000191	0.0021	CbGeAlD
Sorafenib—Infection—Hydroxyurea—brain cancer	0.000191	0.00204	CcSEcCtD
Sorafenib—Immune system disorder—Temozolomide—brain cancer	0.000191	0.00204	CcSEcCtD
Sorafenib—Mediastinal disorder—Temozolomide—brain cancer	0.000191	0.00204	CcSEcCtD
Sorafenib—Malnutrition—Carmustine—brain cancer	0.000191	0.00204	CcSEcCtD
Sorafenib—Erythema—Carmustine—brain cancer	0.000191	0.00204	CcSEcCtD
Sorafenib—FLT1—central nervous system—brain cancer	0.00019	0.00208	CbGeAlD
Sorafenib—Pneumonia—Etoposide—brain cancer	0.00019	0.00203	CcSEcCtD
Sorafenib—Nervous system disorder—Hydroxyurea—brain cancer	0.000189	0.00202	CcSEcCtD
Sorafenib—RAF1—central nervous system—brain cancer	0.000189	0.00207	CbGeAlD
Sorafenib—Infestation—Etoposide—brain cancer	0.000189	0.00202	CcSEcCtD
Sorafenib—Infestation NOS—Etoposide—brain cancer	0.000189	0.00202	CcSEcCtD
Sorafenib—Thrombocytopenia—Hydroxyurea—brain cancer	0.000188	0.00201	CcSEcCtD
Sorafenib—UGT1A1—endocrine gland—brain cancer	0.000188	0.00207	CbGeAlD
Sorafenib—EPHB6—central nervous system—brain cancer	0.000188	0.00206	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000187	0.002	CcSEcCtD
Sorafenib—Alopecia—Temozolomide—brain cancer	0.000187	0.002	CcSEcCtD
Sorafenib—Skin disorder—Hydroxyurea—brain cancer	0.000187	0.002	CcSEcCtD
Sorafenib—Acute coronary syndrome—Etoposide—brain cancer	0.000186	0.00199	CcSEcCtD
Sorafenib—FLT1—cerebellum—brain cancer	0.000186	0.00204	CbGeAlD
Sorafenib—Renal failure—Etoposide—brain cancer	0.000185	0.00198	CcSEcCtD
Sorafenib—Mental disorder—Temozolomide—brain cancer	0.000185	0.00198	CcSEcCtD
Sorafenib—CYP2D6—hindbrain—brain cancer	0.000185	0.00203	CbGeAlD
Sorafenib—Myocardial infarction—Etoposide—brain cancer	0.000185	0.00198	CcSEcCtD
Sorafenib—Neuropathy peripheral—Etoposide—brain cancer	0.000185	0.00198	CcSEcCtD
Sorafenib—RAF1—cerebellum—brain cancer	0.000184	0.00203	CbGeAlD
Sorafenib—Malnutrition—Temozolomide—brain cancer	0.000184	0.00197	CcSEcCtD
Sorafenib—Erythema—Temozolomide—brain cancer	0.000184	0.00197	CcSEcCtD
Sorafenib—Jaundice—Etoposide—brain cancer	0.000184	0.00196	CcSEcCtD
Sorafenib—Stomatitis—Etoposide—brain cancer	0.000184	0.00196	CcSEcCtD
Sorafenib—Anorexia—Hydroxyurea—brain cancer	0.000183	0.00196	CcSEcCtD
Sorafenib—EPHB6—cerebellum—brain cancer	0.000183	0.00201	CbGeAlD
Sorafenib—Hypersensitivity—Procarbazine—brain cancer	0.000183	0.00196	CcSEcCtD
Sorafenib—MAP3K7—brain—brain cancer	0.000181	0.00199	CbGeAlD
Sorafenib—Dysgeusia—Temozolomide—brain cancer	0.00018	0.00193	CcSEcCtD
Sorafenib—STK10—central nervous system—brain cancer	0.00018	0.00197	CbGeAlD
Sorafenib—KIT—midbrain—brain cancer	0.00018	0.00197	CbGeAlD
Sorafenib—Asthenia—Procarbazine—brain cancer	0.000178	0.00191	CcSEcCtD
Sorafenib—Hepatobiliary disease—Etoposide—brain cancer	0.000178	0.00191	CcSEcCtD
Sorafenib—MAP2K5—endocrine gland—brain cancer	0.000178	0.00196	CbGeAlD
Sorafenib—KDR—endocrine gland—brain cancer	0.000178	0.00196	CbGeAlD
Sorafenib—PDGFRA—central nervous system—brain cancer	0.000178	0.00195	CbGeAlD
Sorafenib—Anaemia—Carmustine—brain cancer	0.000176	0.00188	CcSEcCtD
Sorafenib—Pruritus—Procarbazine—brain cancer	0.000176	0.00188	CcSEcCtD
Sorafenib—MAP2K5—head—brain cancer	0.000176	0.00193	CbGeAlD
Sorafenib—KDR—head—brain cancer	0.000176	0.00193	CbGeAlD
Sorafenib—STK10—cerebellum—brain cancer	0.000176	0.00193	CbGeAlD
Sorafenib—PDGFRB—midbrain—brain cancer	0.000175	0.00193	CbGeAlD
Sorafenib—MKNK2—brain—brain cancer	0.000175	0.00193	CbGeAlD
Sorafenib—KIT—spinal cord—brain cancer	0.000175	0.00192	CbGeAlD
Sorafenib—PDGFRA—cerebellum—brain cancer	0.000174	0.00191	CbGeAlD
Sorafenib—CSF1R—endocrine gland—brain cancer	0.000174	0.00191	CbGeAlD
Sorafenib—MKNK1—brain—brain cancer	0.000173	0.0019	CbGeAlD
Sorafenib—Dyspnoea—Hydroxyurea—brain cancer	0.000172	0.00183	CcSEcCtD
Sorafenib—CSF1R—head—brain cancer	0.000172	0.00188	CbGeAlD
Sorafenib—PDGFRB—spinal cord—brain cancer	0.000171	0.00188	CbGeAlD
Sorafenib—RET—brain—brain cancer	0.000171	0.00188	CbGeAlD
Sorafenib—Leukopenia—Carmustine—brain cancer	0.000171	0.00182	CcSEcCtD
Sorafenib—Anaemia—Temozolomide—brain cancer	0.00017	0.00182	CcSEcCtD
Sorafenib—Diarrhoea—Procarbazine—brain cancer	0.00017	0.00182	CcSEcCtD
Sorafenib—Dyspepsia—Hydroxyurea—brain cancer	0.000169	0.00181	CcSEcCtD
Sorafenib—Angioedema—Temozolomide—brain cancer	0.000168	0.0018	CcSEcCtD
Sorafenib—Decreased appetite—Hydroxyurea—brain cancer	0.000167	0.00179	CcSEcCtD
Sorafenib—Urinary tract disorder—Etoposide—brain cancer	0.000167	0.00179	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000166	0.00178	CcSEcCtD
Sorafenib—Urethral disorder—Etoposide—brain cancer	0.000166	0.00177	CcSEcCtD
Sorafenib—Fatigue—Hydroxyurea—brain cancer	0.000166	0.00177	CcSEcCtD
Sorafenib—Leukopenia—Temozolomide—brain cancer	0.000165	0.00176	CcSEcCtD
Sorafenib—Hypertension—Carmustine—brain cancer	0.000165	0.00176	CcSEcCtD
Sorafenib—Pain—Hydroxyurea—brain cancer	0.000165	0.00176	CcSEcCtD
Sorafenib—Constipation—Hydroxyurea—brain cancer	0.000165	0.00176	CcSEcCtD
Sorafenib—Dizziness—Procarbazine—brain cancer	0.000164	0.00176	CcSEcCtD
Sorafenib—Myalgia—Carmustine—brain cancer	0.000162	0.00173	CcSEcCtD
Sorafenib—HTR2C—medulla oblongata—brain cancer	0.000162	0.00178	CbGeAlD
Sorafenib—Cough—Temozolomide—brain cancer	0.000161	0.00172	CcSEcCtD
Sorafenib—MAP2K5—central nervous system—brain cancer	0.00016	0.00176	CbGeAlD
Sorafenib—KDR—central nervous system—brain cancer	0.00016	0.00176	CbGeAlD
Sorafenib—Erythema multiforme—Etoposide—brain cancer	0.00016	0.00171	CcSEcCtD
Sorafenib—Hypertension—Temozolomide—brain cancer	0.000159	0.0017	CcSEcCtD
Sorafenib—RALBP1—brain—brain cancer	0.000158	0.00174	CbGeAlD
Sorafenib—Vomiting—Procarbazine—brain cancer	0.000158	0.00169	CcSEcCtD
Sorafenib—KIT—endocrine gland—brain cancer	0.000158	0.00173	CbGeAlD
Sorafenib—Flushing—Etoposide—brain cancer	0.000157	0.00168	CcSEcCtD
Sorafenib—Cardiac disorder—Etoposide—brain cancer	0.000157	0.00168	CcSEcCtD
Sorafenib—KDR—cerebellum—brain cancer	0.000157	0.00172	CbGeAlD
Sorafenib—MAP2K5—cerebellum—brain cancer	0.000157	0.00172	CbGeAlD
Sorafenib—Arthralgia—Temozolomide—brain cancer	0.000157	0.00168	CcSEcCtD
Sorafenib—Myalgia—Temozolomide—brain cancer	0.000157	0.00168	CcSEcCtD
Sorafenib—Rash—Procarbazine—brain cancer	0.000157	0.00168	CcSEcCtD
Sorafenib—Dermatitis—Procarbazine—brain cancer	0.000157	0.00167	CcSEcCtD
Sorafenib—CSF1R—central nervous system—brain cancer	0.000157	0.00172	CbGeAlD
Sorafenib—KIT—head—brain cancer	0.000156	0.00171	CbGeAlD
Sorafenib—Headache—Procarbazine—brain cancer	0.000156	0.00166	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000156	0.00166	CcSEcCtD
Sorafenib—Infection—Carmustine—brain cancer	0.000155	0.00165	CcSEcCtD
Sorafenib—PDGFRB—endocrine gland—brain cancer	0.000154	0.00169	CbGeAlD
Sorafenib—Angiopathy—Etoposide—brain cancer	0.000154	0.00164	CcSEcCtD
Sorafenib—Dry mouth—Temozolomide—brain cancer	0.000153	0.00164	CcSEcCtD
Sorafenib—CSF1R—cerebellum—brain cancer	0.000153	0.00168	CbGeAlD
Sorafenib—Immune system disorder—Etoposide—brain cancer	0.000153	0.00163	CcSEcCtD
Sorafenib—Mediastinal disorder—Etoposide—brain cancer	0.000153	0.00163	CcSEcCtD
Sorafenib—Thrombocytopenia—Carmustine—brain cancer	0.000152	0.00163	CcSEcCtD
Sorafenib—PDGFRB—head—brain cancer	0.000152	0.00167	CbGeAlD
Sorafenib—Body temperature increased—Hydroxyurea—brain cancer	0.000152	0.00163	CcSEcCtD
Sorafenib—FLT1—brain—brain cancer	0.000151	0.00165	CbGeAlD
Sorafenib—Anaphylactic shock—Temozolomide—brain cancer	0.00015	0.00161	CcSEcCtD
Sorafenib—RAF1—brain—brain cancer	0.00015	0.00164	CbGeAlD
Sorafenib—Alopecia—Etoposide—brain cancer	0.00015	0.0016	CcSEcCtD
Sorafenib—Infection—Temozolomide—brain cancer	0.000149	0.0016	CcSEcCtD
Sorafenib—EPHB6—brain—brain cancer	0.000149	0.00164	CbGeAlD
Sorafenib—Anorexia—Carmustine—brain cancer	0.000148	0.00158	CcSEcCtD
Sorafenib—HTR2C—midbrain—brain cancer	0.000148	0.00162	CbGeAlD
Sorafenib—Nausea—Procarbazine—brain cancer	0.000148	0.00158	CcSEcCtD
Sorafenib—Nervous system disorder—Temozolomide—brain cancer	0.000147	0.00158	CcSEcCtD
Sorafenib—Thrombocytopenia—Temozolomide—brain cancer	0.000147	0.00157	CcSEcCtD
Sorafenib—Skin disorder—Temozolomide—brain cancer	0.000146	0.00156	CcSEcCtD
Sorafenib—HTR2C—spinal cord—brain cancer	0.000144	0.00158	CbGeAlD
Sorafenib—Dysgeusia—Etoposide—brain cancer	0.000144	0.00154	CcSEcCtD
Sorafenib—Anorexia—Temozolomide—brain cancer	0.000143	0.00153	CcSEcCtD
Sorafenib—STK10—brain—brain cancer	0.000143	0.00157	CbGeAlD
Sorafenib—KIT—central nervous system—brain cancer	0.000142	0.00156	CbGeAlD
Sorafenib—Hypersensitivity—Hydroxyurea—brain cancer	0.000142	0.00151	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000142	0.00151	CcSEcCtD
Sorafenib—Muscle spasms—Etoposide—brain cancer	0.000142	0.00151	CcSEcCtD
Sorafenib—PDGFRA—brain—brain cancer	0.000141	0.00155	CbGeAlD
Sorafenib—ABCB1—blood vessel—brain cancer	0.00014	0.00153	CbGeAlD
Sorafenib—KIT—cerebellum—brain cancer	0.000139	0.00153	CbGeAlD
Sorafenib—PDGFRB—central nervous system—brain cancer	0.000139	0.00152	CbGeAlD
Sorafenib—Dyspnoea—Carmustine—brain cancer	0.000139	0.00148	CcSEcCtD
Sorafenib—Asthenia—Hydroxyurea—brain cancer	0.000138	0.00148	CcSEcCtD
Sorafenib—ABCG2—telencephalon—brain cancer	0.000137	0.00151	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000137	0.00146	CcSEcCtD
Sorafenib—Anaemia—Etoposide—brain cancer	0.000136	0.00146	CcSEcCtD
Sorafenib—PDGFRB—cerebellum—brain cancer	0.000136	0.00149	CbGeAlD
Sorafenib—Decreased appetite—Carmustine—brain cancer	0.000135	0.00144	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Carmustine—brain cancer	0.000134	0.00144	CcSEcCtD
Sorafenib—Dyspnoea—Temozolomide—brain cancer	0.000134	0.00143	CcSEcCtD
Sorafenib—Constipation—Carmustine—brain cancer	0.000133	0.00142	CcSEcCtD
Sorafenib—Pain—Carmustine—brain cancer	0.000133	0.00142	CcSEcCtD
Sorafenib—Dyspepsia—Temozolomide—brain cancer	0.000132	0.00141	CcSEcCtD
Sorafenib—Leukopenia—Etoposide—brain cancer	0.000132	0.00141	CcSEcCtD
Sorafenib—Diarrhoea—Hydroxyurea—brain cancer	0.000132	0.00141	CcSEcCtD
Sorafenib—Decreased appetite—Temozolomide—brain cancer	0.000131	0.0014	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Temozolomide—brain cancer	0.00013	0.00139	CcSEcCtD
Sorafenib—Fatigue—Temozolomide—brain cancer	0.00013	0.00138	CcSEcCtD
Sorafenib—Loss of consciousness—Etoposide—brain cancer	0.00013	0.00138	CcSEcCtD
Sorafenib—Cough—Etoposide—brain cancer	0.000129	0.00137	CcSEcCtD
Sorafenib—Pain—Temozolomide—brain cancer	0.000129	0.00137	CcSEcCtD
Sorafenib—Constipation—Temozolomide—brain cancer	0.000129	0.00137	CcSEcCtD
Sorafenib—HTR2C—head—brain cancer	0.000128	0.00141	CbGeAlD
Sorafenib—KDR—brain—brain cancer	0.000127	0.0014	CbGeAlD
Sorafenib—MAP2K5—brain—brain cancer	0.000127	0.0014	CbGeAlD
Sorafenib—Hypertension—Etoposide—brain cancer	0.000127	0.00136	CcSEcCtD
Sorafenib—Dizziness—Hydroxyurea—brain cancer	0.000127	0.00136	CcSEcCtD
Sorafenib—Gastrointestinal pain—Carmustine—brain cancer	0.000127	0.00136	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000125	0.00133	CcSEcCtD
Sorafenib—CSF1R—brain—brain cancer	0.000124	0.00137	CbGeAlD
Sorafenib—Body temperature increased—Carmustine—brain cancer	0.000123	0.00131	CcSEcCtD
Sorafenib—Abdominal pain—Carmustine—brain cancer	0.000123	0.00131	CcSEcCtD
Sorafenib—Gastrointestinal pain—Temozolomide—brain cancer	0.000123	0.00131	CcSEcCtD
Sorafenib—ABCC4—endocrine gland—brain cancer	0.000123	0.00135	CbGeAlD
Sorafenib—Vomiting—Hydroxyurea—brain cancer	0.000122	0.00131	CcSEcCtD
Sorafenib—Rash—Hydroxyurea—brain cancer	0.000121	0.0013	CcSEcCtD
Sorafenib—Dermatitis—Hydroxyurea—brain cancer	0.000121	0.0013	CcSEcCtD
Sorafenib—ABCC4—head—brain cancer	0.000121	0.00133	CbGeAlD
Sorafenib—Headache—Hydroxyurea—brain cancer	0.000121	0.00129	CcSEcCtD
Sorafenib—HTR2B—head—brain cancer	0.00012	0.00132	CbGeAlD
Sorafenib—Anaphylactic shock—Etoposide—brain cancer	0.00012	0.00129	CcSEcCtD
Sorafenib—Infection—Etoposide—brain cancer	0.000119	0.00128	CcSEcCtD
Sorafenib—Urticaria—Temozolomide—brain cancer	0.000119	0.00128	CcSEcCtD
Sorafenib—Body temperature increased—Temozolomide—brain cancer	0.000119	0.00127	CcSEcCtD
Sorafenib—Abdominal pain—Temozolomide—brain cancer	0.000119	0.00127	CcSEcCtD
Sorafenib—ABCC2—endocrine gland—brain cancer	0.000119	0.0013	CbGeAlD
Sorafenib—Thrombocytopenia—Etoposide—brain cancer	0.000118	0.00126	CcSEcCtD
Sorafenib—HTR2C—central nervous system—brain cancer	0.000117	0.00129	CbGeAlD
Sorafenib—Skin disorder—Etoposide—brain cancer	0.000117	0.00125	CcSEcCtD
Sorafenib—CYP2C8—pituitary gland—brain cancer	0.000115	0.00126	CbGeAlD
Sorafenib—Anorexia—Etoposide—brain cancer	0.000115	0.00123	CcSEcCtD
Sorafenib—Hypersensitivity—Carmustine—brain cancer	0.000115	0.00122	CcSEcCtD
Sorafenib—Nausea—Hydroxyurea—brain cancer	0.000114	0.00122	CcSEcCtD
Sorafenib—KIT—brain—brain cancer	0.000113	0.00124	CbGeAlD
Sorafenib—ABCG2—pituitary gland—brain cancer	0.000112	0.00123	CbGeAlD
Sorafenib—Asthenia—Carmustine—brain cancer	0.000112	0.00119	CcSEcCtD
Sorafenib—Hypersensitivity—Temozolomide—brain cancer	0.000111	0.00118	CcSEcCtD
Sorafenib—ABCC4—central nervous system—brain cancer	0.000111	0.00121	CbGeAlD
Sorafenib—PDGFRB—brain—brain cancer	0.00011	0.00121	CbGeAlD
Sorafenib—HTR2B—central nervous system—brain cancer	0.00011	0.00121	CbGeAlD
Sorafenib—ABCG2—medulla oblongata—brain cancer	0.000108	0.00118	CbGeAlD
Sorafenib—Asthenia—Temozolomide—brain cancer	0.000108	0.00115	CcSEcCtD
Sorafenib—Dyspnoea—Etoposide—brain cancer	0.000107	0.00115	CcSEcCtD
Sorafenib—Diarrhoea—Carmustine—brain cancer	0.000106	0.00114	CcSEcCtD
Sorafenib—Pruritus—Temozolomide—brain cancer	0.000106	0.00114	CcSEcCtD
Sorafenib—CYP2D6—brainstem—brain cancer	0.000106	0.00116	CbGeAlD
Sorafenib—CYP2B6—gonad—brain cancer	0.000106	0.00116	CbGeAlD
Sorafenib—Decreased appetite—Etoposide—brain cancer	0.000105	0.00112	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Etoposide—brain cancer	0.000104	0.00111	CcSEcCtD
Sorafenib—Fatigue—Etoposide—brain cancer	0.000104	0.00111	CcSEcCtD
Sorafenib—Dizziness—Carmustine—brain cancer	0.000103	0.0011	CcSEcCtD
Sorafenib—Pain—Etoposide—brain cancer	0.000103	0.0011	CcSEcCtD
Sorafenib—Constipation—Etoposide—brain cancer	0.000103	0.0011	CcSEcCtD
Sorafenib—Diarrhoea—Temozolomide—brain cancer	0.000103	0.0011	CcSEcCtD
Sorafenib—CYP2C19—endocrine gland—brain cancer	0.000102	0.00112	CbGeAlD
Sorafenib—Dizziness—Temozolomide—brain cancer	9.94e-05	0.00106	CcSEcCtD
Sorafenib—Vomiting—Carmustine—brain cancer	9.89e-05	0.00106	CcSEcCtD
Sorafenib—ABCG2—midbrain—brain cancer	9.86e-05	0.00108	CbGeAlD
Sorafenib—Gastrointestinal pain—Etoposide—brain cancer	9.84e-05	0.00105	CcSEcCtD
Sorafenib—Rash—Carmustine—brain cancer	9.81e-05	0.00105	CcSEcCtD
Sorafenib—Dermatitis—Carmustine—brain cancer	9.8e-05	0.00105	CcSEcCtD
Sorafenib—Headache—Carmustine—brain cancer	9.74e-05	0.00104	CcSEcCtD
Sorafenib—ABCG2—spinal cord—brain cancer	9.62e-05	0.00106	CbGeAlD
Sorafenib—Vomiting—Temozolomide—brain cancer	9.56e-05	0.00102	CcSEcCtD
Sorafenib—Urticaria—Etoposide—brain cancer	9.56e-05	0.00102	CcSEcCtD
Sorafenib—Body temperature increased—Etoposide—brain cancer	9.51e-05	0.00102	CcSEcCtD
Sorafenib—Abdominal pain—Etoposide—brain cancer	9.51e-05	0.00102	CcSEcCtD
Sorafenib—Rash—Temozolomide—brain cancer	9.48e-05	0.00101	CcSEcCtD
Sorafenib—Dermatitis—Temozolomide—brain cancer	9.47e-05	0.00101	CcSEcCtD
Sorafenib—Headache—Temozolomide—brain cancer	9.42e-05	0.00101	CcSEcCtD
Sorafenib—CYP2D6—telencephalon—brain cancer	9.41e-05	0.00103	CbGeAlD
Sorafenib—HTR2C—brain—brain cancer	9.3e-05	0.00102	CbGeAlD
Sorafenib—Nausea—Carmustine—brain cancer	9.24e-05	0.000987	CcSEcCtD
Sorafenib—Nausea—Temozolomide—brain cancer	8.93e-05	0.000954	CcSEcCtD
Sorafenib—CYP2C8—endocrine gland—brain cancer	8.91e-05	0.000978	CbGeAlD
Sorafenib—Hypersensitivity—Etoposide—brain cancer	8.86e-05	0.000947	CcSEcCtD
Sorafenib—ABCC4—brain—brain cancer	8.78e-05	0.000964	CbGeAlD
Sorafenib—HTR2B—brain—brain cancer	8.73e-05	0.000959	CbGeAlD
Sorafenib—Asthenia—Etoposide—brain cancer	8.63e-05	0.000922	CcSEcCtD
Sorafenib—Pruritus—Etoposide—brain cancer	8.51e-05	0.000909	CcSEcCtD
Sorafenib—CYP1A2—endocrine gland—brain cancer	8.34e-05	0.000915	CbGeAlD
Sorafenib—Diarrhoea—Etoposide—brain cancer	8.23e-05	0.000879	CcSEcCtD
Sorafenib—CYP3A5—endocrine gland—brain cancer	8.04e-05	0.000883	CbGeAlD
Sorafenib—CYP2B6—endocrine gland—brain cancer	7.99e-05	0.000877	CbGeAlD
Sorafenib—Dizziness—Etoposide—brain cancer	7.95e-05	0.00085	CcSEcCtD
Sorafenib—CYP2C9—endocrine gland—brain cancer	7.91e-05	0.000869	CbGeAlD
Sorafenib—CYP2B6—head—brain cancer	7.89e-05	0.000866	CbGeAlD
Sorafenib—Vomiting—Etoposide—brain cancer	7.65e-05	0.000817	CcSEcCtD
Sorafenib—ABCG2—cerebellum—brain cancer	7.63e-05	0.000838	CbGeAlD
Sorafenib—Rash—Etoposide—brain cancer	7.58e-05	0.00081	CcSEcCtD
Sorafenib—Dermatitis—Etoposide—brain cancer	7.58e-05	0.00081	CcSEcCtD
Sorafenib—Headache—Etoposide—brain cancer	7.53e-05	0.000805	CcSEcCtD
Sorafenib—CYP2B6—central nervous system—brain cancer	7.2e-05	0.000791	CbGeAlD
Sorafenib—Nausea—Etoposide—brain cancer	7.14e-05	0.000764	CcSEcCtD
Sorafenib—ABCB1—telencephalon—brain cancer	6.77e-05	0.000744	CbGeAlD
Sorafenib—CYP2C8—brain—brain cancer	6.37e-05	0.0007	CbGeAlD
Sorafenib—ABCG2—brain—brain cancer	6.2e-05	0.00068	CbGeAlD
Sorafenib—CYP3A4—endocrine gland—brain cancer	6.03e-05	0.000663	CbGeAlD
Sorafenib—CYP2D6—endocrine gland—brain cancer	5.94e-05	0.000652	CbGeAlD
Sorafenib—CYP2D6—head—brain cancer	5.86e-05	0.000644	CbGeAlD
Sorafenib—CYP2B6—brain—brain cancer	5.72e-05	0.000628	CbGeAlD
Sorafenib—ABCB1—gonad—brain cancer	5.65e-05	0.000621	CbGeAlD
Sorafenib—ABCB1—pituitary gland—brain cancer	5.51e-05	0.000605	CbGeAlD
Sorafenib—CYP3A4—central nervous system—brain cancer	5.44e-05	0.000597	CbGeAlD
Sorafenib—CYP2D6—central nervous system—brain cancer	5.35e-05	0.000588	CbGeAlD
Sorafenib—ABCB1—medulla oblongata—brain cancer	5.32e-05	0.000584	CbGeAlD
Sorafenib—CYP2D6—cerebellum—brain cancer	5.23e-05	0.000574	CbGeAlD
Sorafenib—ABCB1—midbrain—brain cancer	4.86e-05	0.000534	CbGeAlD
Sorafenib—ABCB1—spinal cord—brain cancer	4.74e-05	0.000521	CbGeAlD
Sorafenib—ABCB1—endocrine gland—brain cancer	4.27e-05	0.000469	CbGeAlD
Sorafenib—CYP2D6—brain—brain cancer	4.25e-05	0.000466	CbGeAlD
Sorafenib—ABCB1—head—brain cancer	4.22e-05	0.000463	CbGeAlD
Sorafenib—ABCB1—central nervous system—brain cancer	3.85e-05	0.000423	CbGeAlD
Sorafenib—ABCB1—cerebellum—brain cancer	3.76e-05	0.000413	CbGeAlD
Sorafenib—ABCB1—brain—brain cancer	3.06e-05	0.000336	CbGeAlD
Sorafenib—CYP2C8—Metabolism—ENO2—brain cancer	4.08e-06	3.29e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IRS2—brain cancer	4.08e-06	3.29e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SPP1—brain cancer	4.06e-06	3.27e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—IL2—brain cancer	4.06e-06	3.27e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MYC—brain cancer	4.06e-06	3.27e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—CTNNB1—brain cancer	4.06e-06	3.27e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—ERBB2—brain cancer	4.01e-06	3.23e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—CTNNB1—brain cancer	4e-06	3.22e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CTNNB1—brain cancer	4e-06	3.22e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—ERBB2—brain cancer	4e-06	3.22e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PDGFRA—brain cancer	3.99e-06	3.22e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—EGFR—brain cancer	3.97e-06	3.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—EGFR—brain cancer	3.97e-06	3.2e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	3.97e-06	3.19e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—RELA—brain cancer	3.94e-06	3.17e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VAV1—brain cancer	3.93e-06	3.17e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL2—brain cancer	3.93e-06	3.17e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—RELA—brain cancer	3.92e-06	3.16e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL2—brain cancer	3.92e-06	3.16e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HES1—brain cancer	3.92e-06	3.16e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—ERBB2—brain cancer	3.91e-06	3.15e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—ERBB2—brain cancer	3.9e-06	3.14e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SPP1—brain cancer	3.88e-06	3.12e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—STAT3—brain cancer	3.87e-06	3.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—brain cancer	3.86e-06	3.11e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—RELA—brain cancer	3.84e-06	3.09e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—ERBB2—brain cancer	3.81e-06	3.07e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—APC—brain cancer	3.81e-06	3.07e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CG—brain cancer	3.81e-06	3.07e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—APC—brain cancer	3.81e-06	3.07e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CG—brain cancer	3.81e-06	3.07e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CTNNB1—brain cancer	3.8e-06	3.06e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2C9—brain cancer	3.79e-06	3.05e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CTNNB1—brain cancer	3.79e-06	3.05e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.75e-06	3.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PDGFRA—brain cancer	3.73e-06	3.01e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—brain cancer	3.7e-06	2.98e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—CTNNB1—brain cancer	3.69e-06	2.97e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL2—brain cancer	3.69e-06	2.97e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IRS2—brain cancer	3.68e-06	2.96e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ENO2—brain cancer	3.64e-06	2.94e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SPP1—brain cancer	3.62e-06	2.92e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—APC—brain cancer	3.61e-06	2.91e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CG—brain cancer	3.61e-06	2.91e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—APC—brain cancer	3.6e-06	2.9e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CG—brain cancer	3.6e-06	2.9e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—ERBB2—brain cancer	3.6e-06	2.9e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—IDH1—brain cancer	3.59e-06	2.89e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—MYC—brain cancer	3.57e-06	2.88e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ENO2—brain cancer	3.56e-06	2.87e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CG—brain cancer	3.56e-06	2.87e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CG—brain cancer	3.56e-06	2.87e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL2—brain cancer	3.55e-06	2.86e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—STAT3—brain cancer	3.54e-06	2.85e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL2—brain cancer	3.53e-06	2.85e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—EGFR—brain cancer	3.51e-06	2.83e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IRS2—brain cancer	3.51e-06	2.82e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CTNNB1—brain cancer	3.5e-06	2.82e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—RELA—brain cancer	3.5e-06	2.82e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CTNNB1—brain cancer	3.5e-06	2.82e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—STAT3—brain cancer	3.49e-06	2.81e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—STAT3—brain cancer	3.49e-06	2.81e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—ERBB2—brain cancer	3.48e-06	2.8e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CCND1—brain cancer	3.46e-06	2.78e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL2—brain cancer	3.46e-06	2.78e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL2—brain cancer	3.45e-06	2.78e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.42e-06	2.76e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CTNNB1—brain cancer	3.42e-06	2.76e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CTNNB1—brain cancer	3.41e-06	2.75e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HES1—brain cancer	3.38e-06	2.72e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CCND1—brain cancer	3.37e-06	2.71e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ENO2—brain cancer	3.35e-06	2.7e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CTNNB1—brain cancer	3.34e-06	2.69e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—brain cancer	3.33e-06	2.69e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ENO2—brain cancer	3.32e-06	2.68e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—STAT3—brain cancer	3.31e-06	2.67e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—STAT3—brain cancer	3.3e-06	2.66e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—RELA—brain cancer	3.3e-06	2.66e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MYC—brain cancer	3.29e-06	2.65e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—ERBB2—brain cancer	3.28e-06	2.64e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2—brain cancer	3.28e-06	2.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IRS2—brain cancer	3.28e-06	2.64e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—RELA—brain cancer	3.27e-06	2.63e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—ERBB2—brain cancer	3.25e-06	2.62e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—APC—brain cancer	3.25e-06	2.61e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CG—brain cancer	3.25e-06	2.61e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—BSG—brain cancer	3.22e-06	2.6e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PDGFRA—brain cancer	3.22e-06	2.59e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—STAT3—brain cancer	3.22e-06	2.59e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—EGFR—brain cancer	3.21e-06	2.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—ERBB2—brain cancer	3.21e-06	2.58e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—EGFR—brain cancer	3.17e-06	2.55e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—EGFR—brain cancer	3.17e-06	2.55e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—brain cancer	3.15e-06	2.54e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CTNNB1—brain cancer	3.15e-06	2.54e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SPP1—brain cancer	3.13e-06	2.52e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—APC—brain cancer	3.1e-06	2.49e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CG—brain cancer	3.1e-06	2.49e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—STAT3—brain cancer	3.06e-06	2.46e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—STAT3—brain cancer	3.05e-06	2.45e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CTNNB1—brain cancer	3.04e-06	2.45e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CG—brain cancer	3.02e-06	2.43e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—VEGFA—brain cancer	3.01e-06	2.43e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EGFR—brain cancer	3.01e-06	2.42e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EGFR—brain cancer	3e-06	2.42e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CG—brain cancer	2.99e-06	2.41e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MYC—brain cancer	2.99e-06	2.41e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—STAT3—brain cancer	2.98e-06	2.4e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—brain cancer	2.98e-06	2.4e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—RELA—brain cancer	2.97e-06	2.4e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—RELA—brain cancer	2.97e-06	2.4e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—STAT3—brain cancer	2.97e-06	2.39e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—brain cancer	2.97e-06	2.39e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—ERBB2—brain cancer	2.96e-06	2.38e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—ERBB2—brain cancer	2.96e-06	2.38e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—brain cancer	2.94e-06	2.37e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—VEGFA—brain cancer	2.94e-06	2.36e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—EGFR—brain cancer	2.93e-06	2.36e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.93e-06	2.36e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—STAT3—brain cancer	2.91e-06	2.34e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCND1—brain cancer	2.9e-06	2.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CG—brain cancer	2.89e-06	2.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—APC—brain cancer	2.89e-06	2.33e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCND1—brain cancer	2.87e-06	2.31e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CTNNB1—brain cancer	2.87e-06	2.31e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CTNNB1—brain cancer	2.84e-06	2.29e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ENO2—brain cancer	2.84e-06	2.29e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MYC—brain cancer	2.84e-06	2.29e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MYC—brain cancer	2.83e-06	2.28e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IRS2—brain cancer	2.83e-06	2.28e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—RELA—brain cancer	2.82e-06	2.27e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—EGFR—brain cancer	2.82e-06	2.27e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—RELA—brain cancer	2.82e-06	2.27e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CTNNB1—brain cancer	2.81e-06	2.26e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—ERBB2—brain cancer	2.81e-06	2.26e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—ERBB2—brain cancer	2.8e-06	2.25e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EGFR—brain cancer	2.78e-06	2.24e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—IDH1—brain cancer	2.77e-06	2.23e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MYC—brain cancer	2.77e-06	2.23e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EGFR—brain cancer	2.77e-06	2.23e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—STAT3—brain cancer	2.75e-06	2.21e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EGFR—brain cancer	2.71e-06	2.18e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EGFR—brain cancer	2.7e-06	2.18e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MYC—brain cancer	2.7e-06	2.18e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—brain cancer	2.68e-06	2.16e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—brain cancer	2.68e-06	2.16e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—STAT3—brain cancer	2.65e-06	2.13e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EGFR—brain cancer	2.64e-06	2.13e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—EGFR—brain cancer	2.64e-06	2.12e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCND1—brain cancer	2.61e-06	2.1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCND1—brain cancer	2.61e-06	2.1e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CTNNB1—brain cancer	2.59e-06	2.08e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CTNNB1—brain cancer	2.59e-06	2.08e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MYC—brain cancer	2.55e-06	2.05e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—brain cancer	2.54e-06	2.05e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—RELA—brain cancer	2.54e-06	2.04e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—brain cancer	2.54e-06	2.04e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—brain cancer	2.52e-06	2.03e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ERBB2—brain cancer	2.52e-06	2.03e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—brain cancer	2.5e-06	2.01e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—STAT3—brain cancer	2.5e-06	2.01e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—APC—brain cancer	2.5e-06	2.01e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CG—brain cancer	2.5e-06	2.01e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EGFR—brain cancer	2.5e-06	2.01e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCND1—brain cancer	2.48e-06	2e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—STAT3—brain cancer	2.48e-06	1.99e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCND1—brain cancer	2.47e-06	1.99e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CTNNB1—brain cancer	2.45e-06	1.98e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CTNNB1—brain cancer	2.45e-06	1.97e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—STAT3—brain cancer	2.45e-06	1.97e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—RELA—brain cancer	2.42e-06	1.95e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EGFR—brain cancer	2.41e-06	1.94e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ERBB2—brain cancer	2.4e-06	1.94e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—brain cancer	2.32e-06	1.87e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—brain cancer	2.3e-06	1.85e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—brain cancer	2.28e-06	1.84e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—brain cancer	2.28e-06	1.83e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—brain cancer	2.28e-06	1.83e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—brain cancer	2.28e-06	1.83e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EGFR—brain cancer	2.28e-06	1.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—brain cancer	2.27e-06	1.83e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EGFR—brain cancer	2.27e-06	1.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—RELA—brain cancer	2.26e-06	1.82e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—STAT3—brain cancer	2.25e-06	1.82e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—STAT3—brain cancer	2.25e-06	1.82e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EGFR—brain cancer	2.25e-06	1.81e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ERBB2—brain cancer	2.25e-06	1.81e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCND1—brain cancer	2.23e-06	1.79e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EGFR—brain cancer	2.22e-06	1.79e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—brain cancer	2.22e-06	1.79e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CG—brain cancer	2.21e-06	1.78e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CTNNB1—brain cancer	2.21e-06	1.78e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO2—brain cancer	2.19e-06	1.77e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—brain cancer	2.18e-06	1.75e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CG—brain cancer	2.16e-06	1.74e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—brain cancer	2.16e-06	1.74e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—brain cancer	2.16e-06	1.74e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—STAT3—brain cancer	2.14e-06	1.72e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STAT3—brain cancer	2.13e-06	1.72e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—brain cancer	2.12e-06	1.71e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CTNNB1—brain cancer	2.1e-06	1.69e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—brain cancer	2.09e-06	1.69e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—brain cancer	2.09e-06	1.69e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—brain cancer	2.05e-06	1.65e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—brain cancer	2.05e-06	1.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—brain cancer	2.04e-06	1.64e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—brain cancer	1.99e-06	1.6e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—brain cancer	1.99e-06	1.6e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—brain cancer	1.98e-06	1.6e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CTNNB1—brain cancer	1.97e-06	1.58e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RELA—brain cancer	1.95e-06	1.57e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—brain cancer	1.94e-06	1.57e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—brain cancer	1.94e-06	1.56e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—brain cancer	1.94e-06	1.56e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—brain cancer	1.94e-06	1.56e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—brain cancer	1.92e-06	1.55e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—brain cancer	1.91e-06	1.54e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—brain cancer	1.89e-06	1.52e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CG—brain cancer	1.87e-06	1.51e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—brain cancer	1.85e-06	1.49e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—brain cancer	1.83e-06	1.48e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—brain cancer	1.79e-06	1.44e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—brain cancer	1.76e-06	1.42e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—brain cancer	1.75e-06	1.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—brain cancer	1.73e-06	1.39e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—brain cancer	1.72e-06	1.39e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—brain cancer	1.72e-06	1.39e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—brain cancer	1.71e-06	1.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—brain cancer	1.71e-06	1.38e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—brain cancer	1.7e-06	1.37e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—brain cancer	1.7e-06	1.37e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CG—brain cancer	1.67e-06	1.35e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—brain cancer	1.67e-06	1.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—brain cancer	1.63e-06	1.31e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CG—brain cancer	1.63e-06	1.31e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—brain cancer	1.63e-06	1.31e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—brain cancer	1.59e-06	1.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—brain cancer	1.56e-06	1.25e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CG—brain cancer	1.54e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CG—brain cancer	1.52e-06	1.23e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—brain cancer	1.49e-06	1.2e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—brain cancer	1.48e-06	1.19e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—brain cancer	1.47e-06	1.18e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—brain cancer	1.4e-06	1.13e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—brain cancer	1.37e-06	1.11e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—brain cancer	1.34e-06	1.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—brain cancer	1.31e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CG—brain cancer	1.3e-06	1.05e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—brain cancer	1.13e-06	9.09e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CG—brain cancer	1.01e-06	8.1e-06	CbGpPWpGaD
